Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1984;18 Suppl 2(Suppl 2):157S-160S.
doi: 10.1111/j.1365-2125.1984.tb02593.x.

Angiotensin converting enzyme inhibition in heart failure

J G Cleland, H J Dargie, J I Robertson
Clinical Trial

Angiotensin converting enzyme inhibition in heart failure

J G Cleland et al. Br J Clin Pharmacol. 1984.

Abstract

Captopril, the first orally effective converting enzyme inhibitor, was administered to 14 patients with chronic heart failure for 6 week periods, in a double-blind crossover comparison with placebo. Captopril improved symptoms and exercise performance, while left ventricular internal dimensions were reduced. The fall in blood pressure induced by captopril was well tolerated. Glomerular filtration rate was reduced and effective renal plasma flow increased on captopril. No decline in body weight or total body sodium was seen, suggesting that a natriuresis had not occurred. Serum and total body potassium rose. Ventricular arrhythmias declined.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Am J Cardiol. 1977 Nov;40(5):789-93 - PubMed
    1. JAMA. 1978 Aug 4;240(5):443-6 - PubMed
    1. Am J Cardiol. 1980 Feb;45(2):337-44 - PubMed
    1. Am Heart J. 1982 Nov;104(5 Pt 2):1215-23 - PubMed
    1. Br Heart J. 1983 Jan;49(1):65-76 - PubMed

Publication types